Trial · NCT07889193
Phase I Clinical Trial of Trivalent Inactivated Split Influenza Virus Vaccine (MDCK Cell)
NCT07889193, Phase 1, Not yet recruiting, Sinovac Biotech Co., Ltd
3 sourcestrials-2026-11-12-0.5.0
Cite this record
ConductScience Library. Phase I Clinical Trial of Trivalent Inactivated Split Influenza Virus Vaccine (MDCK Cell). Trials, record NCT07889193. Release trials-2026-11-12-0.5.0, 12 Nov 2026. https://conductscience.org/library/trials/NCT07889193
On this page
Trial
As registered on ClinicalTrials.gov, in the graph's capture of the registry.
- Title
- Phase I Clinical Trial of Trivalent Inactivated Split Influenza Virus Vaccine (MDCK Cell)
- NCT number
- NCT07889193
- Status
- Not yet recruiting
- Phases
- Phase 1
- Enrollment
- 175 participants, estimated
- Lead sponsor
- Sinovac Biotech Co., Ltd
- Conditions
- Seasonal Influenza
- Interventions
- Cell-based Trivalent Split Influenza Virus Vaccine (cTIV), Egg-based Trivalent Split Influenza Virus Vaccine (eTIV), Placebo
- First posted
- 2026-10-22
- Last updated
- 2026-10-22
Source ClinicalTrials.gov
Registered outcomes8
Each outcome the trial registered, primary first, in ClinicalTrials.gov's words.
| List | Outcome | Time frame | Description |
|---|---|---|---|
| Primary | Incidence of adverse reactions | 0-28 days after each dose | Incidence of adverse reactions from Day 0 to Day 28 after each dose |
| Secondary | Incidence of adverse reactions | 0-7 days after each dose | Incidence of adverse reactions from Day 0 to Day 7 after each dose |
| Secondary | Incidence of serious adverse events(SAEs) | From the first dose up to 6 months after the last dose | Incidence of SAEs from the first dose up to 6 months after the last dose |
| Secondary | Incidence of abnormal and clinically significant hematology, serum biochemistry and urinalysis parameters on Day 3 after vaccination | Day 3 after vaccination | Incidence of laboratory abnormalities with clinical significance in hematology, serum biochemistry and urinalysis collected on Day 3 post-vaccination among trial participants. |
| Secondary | The geometric mean titers (GMTs) of hemagglutination inhibition (HI) antibodies against each antigen 28 days after completion of full vaccination. | Day 28 after completion of full vaccination | GMT for each vaccine-related influenza strain, assessed at Day 28 after full vaccination. |
| Secondary | The geometric mean increase (GMI) of HI antibodies against each antigen 28 days after full vaccination. | Day 28 after full vaccination | GMI for each vaccine-related influenza strain, assessed at Day 28 after full vaccination. |
| Secondary | The seroconversion rates of HI antibodies against each antigen 28 days after full vaccination. | Day 28 after full vaccination | Seroconversion rate for each vaccine-related influenza strain, assessed at Day 28 after full vaccination. |
| Secondary | The seroprotection rates of antibodies against each antigen 28 days after full vaccination. | Day 28 after completion of full vaccination | Seroprotection rate (HI titer ≥1:40) for each vaccine-related influenza strain, assessed at Day 28 after full vaccination. |
Source ClinicalTrials.gov
Outcomes0
Each outcome the trial posted results for, in ClinicalTrials.gov's words.
None in this release.
Results by group0
Each measurement the trial posted, group by group, in the words and numbers it posted.
None in this release.
Participant flow0
How many started, completed or left each group, period by period.
None in this release.
Adverse events0
Each adverse event the trial posted, group by group: the participants affected out of those at risk.
None in this release.
Adverse event totals0
The totals the trial posted for each group.
None in this release.
Papers0
The papers the trial lists on ClinicalTrials.gov.
None in this release.
Grants0
The grants NIH RePORTER links to the trial, newest funded first: NIH's, and some of AHRQ's, CDC's, FDA's and VA's. Each shows its title, principal investigators, organization and funder in its newest year.
None in this release.
Trial comparisons0
Comparisons of the trial's two groups, calculated by ConductScience from the counts it posted.
None in this release.
Tests0
The ConductCognition tests this trial's registered outcomes name, as ScienceGraph matched them in trial-tests-2026-11-12-0.2.1.
None in this release.
Data dates
The day each source was copied for this release.
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this trial from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/trials/v1/NCT07889193
GET https://conductscience.org/api/trials/v1/NCT07889193/registered